NCT03590808View on ClinicalTrials.gov

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

NACompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

December 21, 2018

Study Completion Date

May 30, 2019

Conditions
InfluenzaSolid Carcinoma
Interventions
BIOLOGICAL

Influenza vaccination

Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

Green Cross Corporation
All Listed Sponsors
collaborator

Green Cross Corporation

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT03590808 - Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor | Biotech Hunter | Biotech Hunter